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1. Introduction 
The increase in average life expectancy in many developed countries is generating an aging 
society and an associated increase in age-related health problems. Mammalian aging occurs 
in part because of a decline in the restorative capacity of tissue stem cells. The use of stem 
cells in regenerative medicine promises to revolutionize the treatment of acute and chronic 
degenerative conditions, and stem cell research holds the key to the development of such 
therapies. The hallmark of adult stem cells is their ability to both self-renew and 
differentiate into multiple lineages. This demands a complex and still poorly understood 
network of molecular interactions between diverse cell-intrinsic regulators of self-renewal, 
such as certain Polycomb proteins and the tumor suppressor p16INK4a, both of which are 
absolutely required for the maintenance of certain stem cell population. Recent studies have 
begun to elucidate the molecular mechanisms underlying how stem cells decide between 
life and death, and highlight the importance of balance in their aging pathways. 
2. Aging and stem cells  
Recent advances in medicine research programs, and a better health care planning, have 
great influences in people living in many Western countries, increasing both quality of life 
and average lifespan. With the extension of lifetime, there is increasing interest in slowing or 
reversing the negative effects of aging. The fascinating discovery of tissue-resident adult 
stem and progenitor cells in recent years has led to an explosion of interest in the 
development of novel stem cell-based therapies to improve endogenous regenerative 
capacity or to repair damaged and diseased tissues. 
A major function of stem cells and their differentiation hierarchies may be to preserve 
the DNA integrity of the whole organism. When mutations occur despite certain error-
prevention capacities, potent tumor-suppressor mechanisms such as senescence and 
apoptosis eliminate the damaged stem cell, limiting its replicative expansion. However, 
when unrepaired genetic lesions in stem cells are passed on to their differentiated 
daughters, and accumulate with aging, it is required replacement of dead and non-
functional cells with newly differentiated cells derived from stem- and progenitor-cells. 
To date, the best-studied adult tissue stem cell type is the hematopoietic stem cell (HSC), 
which gives rise to all of the mature blood cells, throughout the life of the organism. 
Hematopoiesis in mammals occurs in distinct temporal waves shifting from the 
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extraembryonic yolk sac and fetal liver in embryos to bone marrow in adults. Primitive 
HSCs are the “true” stem cells, also termed the long-term repopulating HSCs (LT-HSCs), 
because they replenish the pool of blood cells by both maintaining the stem cells and 
allowing daughter cells to differentiate into the lymphoid, myeloid, and erythroid 
lineages. The daily replenishment of blood cells is achieved in large part by divisions and 
subsequent stepwise differentiation of cells descendants of LT-HSC pool, namely short 
term repopulating HSC (ST-HSC), and slightly more committed hematopoietic 
progenitor cells (MPP-HSC). The relative quiescence of LT-HSCs pool protects their 
genomic integrity by reducing the rounds of DNA replication and thus the probability of 
acquiring DNA damage that might compromise multilineage differentiation potential 
and/or render them malignant over time, though they appear to age with the host 
(Orkin and Zon, 2008). The rapid turnover of the hematopoietic system and the 
availability of advanced methods to study HSCs by different markers have led to this 
system being widely used as a model of the effects of aging on stem cell functionality 
(Figure 1). It is worthy to mention that although some aspects of aging may be shared by 
all somatic stem cell fractions, the mechanisms of aging are likely to differ between stem 
cell populations located in specific tissues (for example, intestine, muscle and bone 
marrow). 
 
Fig. 1. The hierarchically primitive cells of the hematopoietic system. Long-Term 
hematopoietic stem cells (LT-HSC) maintain hematopoiesis by coordinating self-renewal, 
and production of short-term HSC (ST-HSC), and subsequently, the multipotent progenitors 
(MPP), which have an incredible capacity to divide and make other types of cells as they 
mature, although a limited ability to self-renew. Ultimately, this generates an array of 
mature blood cells with different functions: lymphoid blood cells (the B-cells; T-cells; natural 
killer or NK cells; plasma cells; dendritic cells and others), and erythroid and myeloid blood 
cells (the erythrocytes or red blood cells; megakaryocytes or platelet producing cells; 
granulocytes such as neutrophils, eosinophils, and basophils; and monocytes which make 
macrophages). The stem and progenitor cells can be purified to near-homogeneity by 
surface markers. For example, LT-HSCs express low levels of lineage markers, high levels of 
Sca1 and CD117/c-KIT receptor, and low levels of CD34 (LSK CD34 lo). With limited 
renewal potential, the ST-HSC pool has a similar surface immunophenotype to LT-HSC 
except that it has higher levels of CD34 (LSK CD34 hi). As ST-HSC in turn proliferates to 
form more differentiated MPP, they increase expression of another surface marker, FLK2 
(LSK CD34 hi Flk2 hi).  
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3. The evidence for stem cell aging 
A growing body of evidence shows that the capacity of stem cells to maintain tissue 
homeostasis declines with age, and suggests that this decline may account for many age-
related phenotypes and diseases (Kirkwood and Austad, 2000). Significantly, 
engraftment of HSCs are capable of serial passages through a succession of mouse 
recipients, outliving the donor mouse (Ross et al., 1982; Siminovitch et al., 1964), though 
it is not possible to exceed up to five successful passages, and the recipients do not 
restore the hematopoietic system to the normal state (Gordon and Blackett, 1998). On the 
other hand, telomere length in blood cells of the transplanted recipient are 1-2 kb shorter 
than those in the donor, when evaluated several years following transplantation 
(Allsopp et al., 2003), which indicates that the level of telomerase is insufficient to 
prevent progressive telomere shortening in HSC. On the other hand, immunophenotypic 
characterization of hematopoietic stem- and progenitor-cell subsets diverges from 
function in old animals. The engraftment efficiency of immunophenotypically selected 
long-term HSCs from old mice approximately is threefold lower than that of the 
equivalent population from young mice (Morrison et al., 1997; Yilmaz et al., 2006). Also, 
age-related changes in stem-cell function include myeloid-biased differentiation and 
decreased homing ability (Liang et al., 2005). In conclusion, it has been extensively 
proved that the properties of HSCs change in several ways as they age, but still is poorly 
known which are the changes in the intrinsic and extrinsic factors involved that regulate 
the self-renewal and multilineage differentiation capacities of these regenerative cells 
(Huang et al., 2007).  
Although the stem- and progenitor-cell proliferation guarantees tissue repair, and thereby 
regeneration, it can also develop hyperproliferative diseases, like cancer, risk that is 
moderated by tumor-suppressors mechanisms. For example, while the increased expression 
of tumor suppressors with age (p53, p16INK4a) inhibits the development of cancer (inducing 
apoptosis or/and senescence) (Krishnamurthy et al., 2004; Ressler et al., 2006), over time it 
may have a negative effect on stem cell functionality, reducing capacity for self-renewal or 
differentiation, and ultimately leading to aging phenotypes (Beausejour and Campisi, 2006; 
Rodier et al., 2007). Thus, it is thought that many of the same mechanisms that contribute to 
cellular aging also act as suppressors of neoplastic growth (Campisi, 2005) (Figure 2). We 
will therefore need a better understanding of age-related changes in stem cell function by 
altering genetically the expression of tumor suppressors, which may improve effective 
longevity-promoting therapies. 
4. Self-renewal regulators in adult HSCs 
Stem cells are crucial for the homeostatic maintenance of mature, functional cells in many 
tissues throughout the lifetime of the animal, and this pool of stem cells must itself be 
maintained (Muller-Sieburg and Sieburg, 2008). This is achieved by self-renewal, a 
specialized cell division in which one or both daughter cells remain undifferentiated and 
retain essentially the same replication potential of the parent. The self-renewal program 
must involve the activity of dedicated regulatory genes (Gazit et al., 2008); but although the 
phenotypic and functional properties of HSCs have been characterized extensively, we have 
only just begun to understand how self-renewal is regulated. 
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Fig. 2. Potential stem cell stage: interplay between aging and cancer. During normal aging, 
stem cells accumulate DNA damage as the consequence of endogenous (telomere 
dysfunction, oxidative stress) or exogenous (oxidative stress, g-irradiation, UV light, and 
others) attacks. This provokes subsequent stress-dependent changes (for example, 
accumulation of the products from the INK4a/ARF locus or telomere shortening), which 
activates checkpoint responses that result in apoptosis or cellular senescence. If these events 
occur in stem/progenitor cells, there is a decrease in the overall number and/or 
functionality of both stem and progenitor cells, leading an alteration of tissue homeostasis 
and regenerative capacity–a phenomenon that might contribute to aging and aged-related 
pathologies. If, instead, DNA mutations that inactivate these checkpoint pathways 
accumulate (for instance, loss of p16INK4a or reactivation of telomerase), then cancer can 
arise. 
Polycomb complex in the maintenance of stemness. PcG proteins regulate self-renewal and 
lineage restriction in stem cells by inducing reversible chromatin modifications. PcG 
proteins have attracted increasing attention in stem cell and cancer stem cell research, given 
that it is now widely recognized that dynamic reprogramming of cells, for instance during 
differentiation, requires alterations to the epigenetic status of genes (Valk-Lingbeek et al., 
2004). These features makes them interesting subjects for stem cell research, since it is 
conceivable that dynamic reprogramming of cells, for instance during differentiation, 
requires alterations in the epigenetic state of gene expression programs. The two major 
multiprotein PcG complexes identified to date, PRC1 and PRC2, function in a cooperative 
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manner to maintain gene silencing (Pietersen et al., 2008) (Table 1). PRC2 initiates silencing, 
whereas PRC1 maintains and stabilizes gene repression. PRC2 contains histone 
methyltransferases (HMTs) that methylate lysines 9 and 27 on histone H3 and lysine 26 on 
histone H1. Deletion of PRC2 genes in mice results in early embryonic death, underscoring 
their importance in development. PRC1 recognizes the H3 lysine 27 methyl group added by 
PRC2 (Valk-Lingbeek et al., 2004), and subsequently the monoubiquityl-ligase activity of the 
PRC1 proteins Bmi1 or Ring1A/B toward histone H2A generates uH2AK119, which 
prevents access of the transcription machinery and facilitates chromatin compaction (Wang 
et al., 2004). Mouse mutants of most PRC1 members, in spite of displaying homeotic 
transformations, survive until birth as a result of partial functional redundancy provided by 
homologues, an exception being Ring1B-deficient mice (Voncken et al., 2003).  
PRC2 is recruited to target genes by the cofactor jARID2 (jumonji/ARID domain-containing 
2). Paradoxically, jARID2 also seems to inhibit PRC2 methyltransferase activity and may 
therefore regulate both the targeting and fine-tuning of PRC2 activity in stem cells and 
during differentiation (Panning, 2010). Once PRC1 recognizes and binds the H3K27me3 
mark added by PRC2, it recruits additional proteins to establish the repressed chromatin 
configuration (Jones and Baylin, 2007). Gene promoters marked with H3K27me3 in ESCs are 
significantly more likely than other promoters to become methylated in cancer (Schlesinger 
et al., 2007). Moreover, the PcG targets in normal prostate cells are the same as those that 
become methylated in prostate cancer (Gal-Yam et al., 2008). Thus, altered chromatin 
structure does not always result in changes in gene expression associated with disease. 
Rather, disease results from the replacement of PcG repressive histone marks with 
methylation directly on DNA, which locks the chromatin in an inactive state, a process 
called epigenetic switching (Gal-Yam et al., 2008). Although the mechanism underlying 
predisposition of PcG targets to DNA methylation is not fully understood, the PRC1 
component Cbx7 (chromobox homologue 7) was recently shown to interact directly with 
DNA (cytosine-5)-methyltransferase (DNMT)1 and DNMT3B at PcG target genes, 
establishing a link between histone and DNA methylation (Mohammad et al., 2009). 
Among PcG proteins, the PRC1 component Bmi1 is a fundamental self-renewal regulator, 
being required for self-renewal of all postnatal stem cell populations studied to date 
(Molofsky et al., 2003; Park et al., 2003; van der Lugt et al., 1994). Bmi1 was originally 
described as a proto-oncogene that induces B and T cell leukemias (van Lohuizen et al., 
1991), and is overexpressed in several human cancers, including mantle cell lymphoma, 
colorectal carcinoma, liver carcinomas, non-small-cell lung cancer, and cerebral tumors such 
as medulloblastomas (Martin-Perez et al., 2010). This evidence has strongly influenced 
cancer research, supporting the above-mentioned theory that cancer is essentially a stem cell 
disorder (Reya et al., 2001). The self-renewal function of Bmi1 in adult stem cells relies 
largely on the silencing of one of its targets, the locus encoding the p16INK4a and ARF 
tumor suppressors (Molofsky et al., 2006). Deletion of p16INK4a and/or ARF partially 
rescues the self-renewal defects observed in various stem cell populations from Bmi1-null 
mice. Nevertheless, as described by the authors, this rescue is incomplete and thus other 
major Bmi1 regulated genes must exist. Candidates for additional Bmi1 targets in the 
context of self renewal are the Hox (homeobox) genes. A subset of Hox genes has been 
implicated in mammalian brain development, and several of them are highly expressed in 
neurospheres formed in vitro from cultured neural stem cells of the subventricular zone of 
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Adapted from Takaaki Konuma et al. Develop. Growth Differ. (2010) 52, 505–516 
Table 1. Principcal components of the Polycomb Group Complexes and their hematopoietic 
defects in mutant mice. 
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Bmi-null mice (Molofsky et al., 2006). More recently, Bmi1 and Ring1A were shown to play 
essential roles in H2A ubiquitylation and Hox gene silencing. Knockout of Bmi1 results in 
significant loss of H2A ubiquitylation and an upregulation of HoxC13 expression, whereas 
Ezh2-mediated H3-K27 methylation is not affected (Cao et al., 2005). Similar findings have 
been described for the HoxC5 gene. However, considering that PcG proteins modify the 
chromatin of large sets of genes (Kirmizis et al., 2004), a great number of additional targets 
are likely to exist. For instance, both PRC2 and Bmi1 have recently been shown to play roles 
in the repression of E-cadherin expression (Yang et al., 2010). Interestingly, PcG genes have 
been shown to have a tumor suppressive function. In Drosophila, PcG proteins repress 
JAK/STAT and Notch signaling activity, whose activation drives disc cell overproliferation 
(Classen et al., 2009). Specifically, the Drosophila complex Psc (posterior sex combs), which 
includes Bmi1, and Suz12 (suppressor of zeste 12) play a tumor suppressive role mediated 
by Wnt repression in follicle stem cells(Li et al., 2010). In mammals, Eed (embryonic 
ectoderm development protein) displays tumor suppressive activity in the mouse 
hematopoietic system (Richie et al., 2002). Thus, PcG genes have been suggested to behave 
either as proto-oncogenes or as tumor suppressors depending on the tissue, cell context, 
developmental stage and gene dosage. 
Bmi1 is regulated by Sonic Hedgehog, providing a direct connection between PcG and a 
major stem cell-specific pathway (Leung et al., 2004). Furthermore, activation of either 
Hedgehog or Notch signaling has been shown to increase Bmi1 expression, whereas siRNA 
knockdown of Bmi1 abrogates the effects of Hedgehog or Notch signaling on sphere 
formation, a functional readout of stemness. Thus the effects of Hedgehog and Notch 
signaling on stem cell self-renewal appear to be largely dependent on Bmi1. A complex 
regulation of Bmi1 is suggested by the fact that distinct Bmi1 regulators have been found in 
different types of cancer, for example Twist1 in head and neck squamous cell carcinoma and 
the Zeb1 (zinc finger E-box binding homeobox 1) – miR-200 pathway in pancreatic cancers 
(Wellner et al., 2009). Furthermore, a single PcG function can be regulated by multiple 
factors, for example Snail1 regulates E-cadherin silencing by PRC2, whereas the action of 
PRC1 on this target is regulated by Twist1 (Yang et al., 2010). 
In summary, PcG proteins, in particular Bmi1, are essential for self-renewal and proliferative 
potential, which are crucial for the maintenance of stemness, acting as a critical failsafe 
mechanism against loss of stem cells in response to senescence signals. In turn, Bmi1 must 
be finely-regulated to prevent uncontrolled replicative expansion and tumor induction. 
Despite the importance of PcG proteins, we are only beginning to unravel how these master 
regulators are themselves regulated to achieve an appropriate balance between ensuring 
stem cell longevity and preventing tumorigenesis. 
The tumor suppressors p16INK4a and ARF. Cell-cycle regulators such as the INK4/ARF locus 
appear to play an important role in the reaction of adult stem cells to stress and aging. The 
INK4/ARF locus plays a central role in tumor suppression, reflected in its inactivation in 
almost 50% of human cancers (Sharpless, 2005). Indeed, this locus is regarded as one of the 
most important anti-oncogenic defenses of the mammalian genome, comparable in 
importance only to p53. The remarkable feature of the INK4/ARF locus is that it encodes 
three tumor suppressors in a genomic segment of about 50 kb: p16INK4a, its related family 
member p15INK4b, and ARF (called p19ARF in mice and p14ARF in humans). The actions of 
p16INK4a, p15INK4b and ARF are well understood. Both p16INK4a and p15INK4b inhibit the kinase 
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activity of CDK4/6-cycD complexes, thus contributing to the maintenance of the active, 
growth-suppressive form of the retinoblastoma (Rb) family of proteins. ARF contributes to 
the stability of p53 by inhibiting the p53-degrading activity of MDM2. Through the 
activation of Rb and p53, the INK4/ARF locus is able to induce cell senescence and cell death 
(Gil and Peters, 2006; Lowe and Sherr, 2003). These tumor suppressors have taken on 
additional importance given recent evidence that at least one product of the locus, p16INK4a, 
also contributes to the decline in the replication potential of self-renewing cells during the 
aging of stem cells. The expression of p16INK4a is relatively low in the HSCs of young mice, 
but is upregulated with age or in response to cellular stresses (Janzen et al., 2006). Although 
the number of immunophenotypic HSCs increases with age in wild-type animals, HSC 
functionality is impaired. In particular, the HSC compartment of old animals is more rapidly 
exhausted by serial transplantation than that of young animals. In contrast, aging has the 
opposite effect on p16INK4a-/- HSCs, with p16INK4a-/- HSCs from old animals substantially 
outperforming young p16INK4a-/- HSCs in serial transplantation assays (Janzen et al., 2006). 
In fact, old p16INK4a-/- HSCs perform as well as young wild-type HSCs in this assay. Thus 
p16INK4a compromises HSC functionality in older mice. Similar results were obtained in 
studies of p16INK4a-/- neuronal stem cells and pancreatic islets (Krishnamurthy et al., 2006; 
Molofsky et al., 2006), revealing a general role for p16INK4a in the regulation of stem cell and 
progenitor cell aging. Therefore, on one face of this coin, p16INK4a acts as a potent tumor 
suppressor that promotes longevity by suppressing the development of cancer, while on the 
flipside, the increase of p16INK4a levels with age impairs the proliferation of stem or 
progenitor cells, ultimately reducing longevity. Thus, p16INK4a seems to balance an 
equilibrium reducing cancer incidence, but also contributing to aging by decreasing stem 
cell self-renewal and proliferation. These observations suggest the provocative but as yet 
unproven notion that mammalian aging results in part from the beneficial effects of tumor 
suppressor proteins (Figure 2). 
The transcription factor p53. Besides p16INK4a tumor suppressor, p53 is also a tumor 
suppressor that influences stem cell self-renewal, tissue regenerative capacity, age-related 
disease, and cancer, which activity is lost in nearly half of all human cancers(Toledo and 
Wahl, 2006). The p53 protein is normally inactive, due in part to its rapid degradation by the 
specific ubiquitin ligase Mdm2. A multitude of stresses converge on p53 through complex, 
and partially understood, signaling pathways that stabilize and modify p53. The analysis of 
the effect of p53 in aging has revealed a dual role that seems to depend on the intensity of 
p53 activity. Overexpression of short isoforms of p53 in mice have greater protection against 
tumor development than wild-type mice, while at the same time they show signs of 
premature aging (Maier et al., 2004; Tyner et al., 2002). However, mouse models of increased 
wild-type p53 activity do not present premature aging. In particular, bacterial artificial 
chromosome transgenic mice that bear a third copy of the p53 locus show a decreased 
cancer incidence but normal longevity and normal onset of aging phenotypes (Garcia-Cao et 
al., 2002; Matheu et al., 2007; Matheu et al., 2004). An additional mouse model, the super-
INK4a/ARF mice, with an extra copy of the entire INK4a/ARF locus (being ARF an activator 
of p53), show a significantly reduced incidence of cancer, although the mice aged normally 
(Matheu et al., 2004). To investigate whether the concomitant expression of both tumor 
suppressors had a synergistic effect, mice that bear a third copy of the p53 locus and a third 
copy of the INK4/ARF locus show increased longevity and delayed aging in a manner that 
cannot be explained by their reduced incidence of cancer (Matheu et al., 2007). Therefore, 
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and though the effects of p53 and INK4/ARF locus expression in aging are context and 
dosage dependent, these results suggest that under physiological aging (labeled by 
moderate increase of still regulated p53 activity), the damaged cells are eliminated by either 
triggering their self-destruction (by apoptosis) or by pulling them out of the proliferative 
pool (by inducing senescence). In contrast, by massive DNA damage, the presence of 
uncontrolled activity of p53 results in excessive elimination of cells by p53 that exhausts the 
capacity of tissue regeneration leading to premature aging.  
The INK4/ARF locus and age-associated phenotypes. p16INK4a and ARF may also be broadly 
important to diseases of aging beyond their function in stem cells. Specifically, three 
research consortia that undertook genome-wide association studies across large, carefully 
annotated patient samples have reported an association between single nucleotide 
polymorphisms (SNPs) near to INK4a/ARF locus and frailty (Melzer et al., 2007), 
atherosclerotic heart disease (ASHD)(Helgadottir et al., 2007) (McPherson et al., 2007), and 
type-2 diabetes (Saxena et al., 2007; Zeggini et al., 2008) in large human cohorts. However, 
few of the associated SNPs near the locus, and associated with these phenotypes, are not in 
linkage disequilibrium with each other, which suggests that more than one polymorphism 
near the locus influences these aging phenotypes. Therefore, although these studies do not 
pinpoint specific polymorphisms that affect the risks of age-related diseases, there are only 
four genes in the vicinity of the mapped polymorphisms: p16INK4a, ARF, p15INK4b, and 
ANRIL (a noncoding RNA). More relative data suggest specific links: p16INK4a expression 
increases with age in pancreatic β cells, and p16INK4a deficiency increases β-cell regenerative 
capacity(Krishnamurthy et al., 2006), providing a mechanism by which polymorphisms that 
affect p16INK4a expression or activity might affect risk for type-2 diabetes. It remains unclear 
whether these polymorphisms influence the risk of frailty and heart disease through their 
effects on tissue regenerative capacity or by mechanisms that are completely independent of 
stem/progenitor cells. Nevertheless, in light of the murine genetic studies that link 
INK4a/ARF locus and stem cell function, proteins encoded by the locus are the strongest 
candidates to mediate the effects of these polymorphisms on the incidence of these common 
diseases that are associated with aging.  
5. Conclusions 
The regenerative capacity of many stem cells declines functionally with age and, this decline 
triggers in part many age-related symptoms, and the development of certain diseases. 
Recent evidences have demonstrated that certain tumor suppressors, like p16INK4a, also 
suppresses the proliferation of stem or progenitor cells in the bone marrow, pancreas and 
brain. Thus, p16INK4a seems to balance equilibrium reducing cancer incidence, which 
promotes longevity, but also decreasing stem cell self-renewal and proliferation, 
compromising tissue regeneration and repair, which are likely to reduce longevity. These 
observations allow us to suggest the provocative but unproved hypothesis that mammalian 
aging results in part from the beneficial efforts of tumor suppressor proteins to interdict 
cancer. In this stage, characterization of how stem cells age, such as the characterization of 
reliable biomarkers, deregulated signaling pathways, loss of self-renewal or acquisition of 
defects in differentiation of stem cells, will contribute to understand the age-associated 
pathophysiological decline. Likewise, it is also essential to figure out the cellular and 
molecular components of stem cell niches, how the niche changes during aging, and 
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whether senescent stem or support cells alter the niche. In summary, the rescue, treatment, 
or replacement of aged and dysfunctional adult stem and progenitor cells may provide 
novel avenues to treat diverse devastating premature aging and age-related disorders 
including hematopoietic and immune disorders, heart failure and cardiovascular diseases, 
neurodegenerative, muscular and gastrointestinal diseases, atherosclerosis and aggressive 
and lethal cancers. 
6. Acknowledgement  
This work was supported by the Human Frontiers Science Program Organization, the 
Spanish Ministries of Science and Innovation (SAF2010-15386) and Health (FIS PI06/0627). 
We thank Simon Bartlett for editing assistance. The CNIC is supported by the Ministry of 
Science and Innovation and the Pro-CNIC Foundation. 
7. Abbreviatons 
PcG, Polycomb Group, PRC1, Polycomb repressive complex 1, PRC2, polycomb repressive 
complex 2. 
8. References 
Allsopp, R.C., Morin, G.B., DePinho, R., Harley, C.B., and Weissman, I.L. (2003). Telomerase 
is required to slow telomere shortening and extend replicative lifespan of HSCs 
during serial transplantation. Blood 102, 517-520. 
Beausejour, C.M., and Campisi, J. (2006). Ageing: balancing regeneration and cancer. Nature 
443, 404-405. 
Campisi, J. (2005). Senescent cells, tumor suppression, and organismal aging: good citizens, 
bad neighbors. Cell 120, 513-522. 
Cao, R., Tsukada, Y., and Zhang, Y. (2005). Role of Bmi-1 and Ring1A in H2A ubiquitylation 
and Hox gene silencing. Mol Cell 20, 845-854. 
Classen, A.K., Bunker, B.D., Harvey, K.F., Vaccari, T., and Bilder, D. (2009). A tumor 
suppressor activity of Drosophila Polycomb genes mediated by JAK-STAT 
signaling. Nat Genet 41, 1150-1155. 
Gal-Yam, E.N., Egger, G., Iniguez, L., Holster, H., Einarsson, S., Zhang, X., Lin, J.C., Liang, 
G., Jones, P.A., and Tanay, A. (2008). Frequent switching of Polycomb repressive 
marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl 
Acad Sci U S A 105, 12979-12984. 
Garcia-Cao, I., Garcia-Cao, M., Martin-Caballero, J., Criado, L.M., Klatt, P., Flores, J.M., 
Weill, J.C., Blasco, M.A., and Serrano, M. (2002). "Super p53" mice exhibit enhanced 
DNA damage response, are tumor resistant and age normally. Embo J 21, 6225-
6235. 
Gazit, R., Weissman, I.L., and Rossi, D.J. (2008). Hematopoietic stem cells and the aging 
hematopoietic system. Semin Hematol 45, 218-224. 
Gil, J., and Peters, G. (2006). Regulation of the INK4b-ARF-INK4a tumour suppressor locus: 
all for one or one for all. Nat Rev Mol Cell Biol 7, 667-677. 
www.intechopen.com
 Insights Into Stem Cell Aging 
 
257 
Gordon, M.Y., and Blackett, N.M. (1998). Reconstruction of the hematopoietic system after 
stem cell transplantation. Cell Transplant 7, 339-344. 
Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, 
A., Sigurdsson, A., Baker, A., Palsson, A., Masson, G., et al. (2007). A common 
variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316, 
1491-1493. 
Huang, X., Cho, S., and Spangrude, G.J. (2007). Hematopoietic stem cells: generation and 
self-renewal. Cell Death Differ 14, 1851-1859. 
Janzen, V., Forkert, R., Fleming, H.E., Saito, Y., Waring, M.T., Dombkowski, D.M., Cheng, T., 
DePinho, R.A., Sharpless, N.E., and Scadden, D.T. (2006). Stem-cell ageing 
modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 443, 421-426. 
Jones, P.A., and Baylin, S.B. (2007). The epigenomics of cancer. Cell 128, 683-692. 
Kirkwood, T.B., and Austad, S.N. (2000). Why do we age? Nature 408, 233-238. 
Kirmizis, A., Bartley, S.M., Kuzmichev, A., Margueron, R., Reinberg, D., Green, R., and 
Farnham, P.J. (2004). Silencing of human polycomb target genes is associated with 
methylation of histone H3 Lys 27. Genes Dev 18, 1592-1605. 
Krishnamurthy, J., Ramsey, M.R., Ligon, K.L., Torrice, C., Koh, A., Bonner-Weir, S., and 
Sharpless, N.E. (2006). p16INK4a induces an age-dependent decline in islet 
regenerative potential. Nature 443, 453-457. 
Krishnamurthy, J., Torrice, C., Ramsey, M.R., Kovalev, G.I., Al-Regaiey, K., Su, L., and 
Sharpless, N.E. (2004). Ink4a/Arf expression is a biomarker of aging. J Clin Invest 
114, 1299-1307. 
Leung, C., Lingbeek, M., Shakhova, O., Liu, J., Tanger, E., Saremaslani, P., Van Lohuizen, 
M., and Marino, S. (2004). Bmi1 is essential for cerebellar development and is 
overexpressed in human medulloblastomas. Nature 428, 337-341. 
Li, X., Han, Y., and Xi, R. (2010). Polycomb group genes Psc and Su(z)2 restrict follicle stem 
cell self-renewal and extrusion by controlling canonical and noncanonical Wnt 
signaling. Genes Dev 24, 933-946. 
Liang, Y., Van Zant, G., and Szilvassy, S.J. (2005). Effects of aging on the homing and 
engraftment of murine hematopoietic stem and progenitor cells. Blood 106, 1479-
1487. 
Lowe, S.W., and Sherr, C.J. (2003). Tumor suppression by Ink4a-Arf: progress and puzzles. 
Curr Opin Genet Dev 13, 77-83. 
Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., 
Thorner, M., and Scrable, H. (2004). Modulation of mammalian life span by the 
short isoform of p53. Genes Dev 18, 306-319. 
Martin-Perez, D., Piris, M.A., and Sanchez-Beato, M. (2010). Polycomb proteins in 
hematologic malignancies. Blood 116, 5465-5475. 
Matheu, A., Maraver, A., Klatt, P., Flores, I., Garcia-Cao, I., Borras, C., Flores, J.M., Viña, J., 
Blasco, M.A., and Serrano, M. (2007). Delayed aging through damage protection by 
the Arf/p53 pathway. Nature in press. 
Matheu, A., Pantoja, C., Efeyan, A., Criado, L.M., Martin-Caballero, J., Flores, J.M., Klatt, P., 
and Serrano, M. (2004). Increased gene dosage of Ink4a/Arf results in cancer 
resistance and normal aging. Genes Dev 18, 2736-2746. 
www.intechopen.com
 Advances in Hematopoietic Stem Cell Research 
 
258 
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D.R., Hinds, 
D.A., Pennacchio, L.A., Tybjaerg-Hansen, A., Folsom, A.R., et al. (2007). A common 
allele on chromosome 9 associated with coronary heart disease. Science 316, 1488-
1491. 
Melzer, D., Frayling, T.M., Murray, A., Hurst, A.J., Harries, L.W., Song, H., Khaw, K., Luben, 
R., Surtees, P.G., Bandinelli, S.S., et al. (2007). A common variant of the p16(INK4a) 
genetic region is associated with physical function in older people. Mech Ageing 
Dev 128, 370-377. 
Mohammad, H.P., Cai, Y., McGarvey, K.M., Easwaran, H., Van Neste, L., Ohm, J.E., 
O'Hagan, H.M., and Baylin, S.B. (2009). Polycomb CBX7 promotes initiation of 
heritable repression of genes frequently silenced with cancer-specific DNA 
hypermethylation. Cancer Res 69, 6322-6330. 
Molofsky, A.V., Pardal, R., Iwashita, T., Park, I.K., Clarke, M.F., and Morrison, S.J. (2003). 
Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor 
proliferation. Nature 425, 962-967. 
Molofsky, A.V., Slutsky, S.G., Joseph, N.M., He, S., Pardal, R., Krishnamurthy, J., Sharpless, 
N.E., and Morrison, S.J. (2006). Increasing p16INK4a expression decreases forebrain 
progenitors and neurogenesis during ageing. Nature 443, 448-452. 
Morrison, S.J., Wright, D.E., Cheshier, S.H., and Weissman, I.L. (1997). Hematopoietic stem 
cells: challenges to expectations. Curr Opin Immunol 9, 216-221. 
Muller-Sieburg, C., and Sieburg, H.B. (2008). Stem cell aging: survival of the laziest? Cell 
Cycle 7, 3798-3804. 
Orkin, S.H., and Zon, L.I. (2008). Hematopoiesis: an evolving paradigm for stem cell 
biology. Cell 132, 631-644. 
Panning, B. (2010). Fine-tuning silencing. Cell Stem Cell 6, 3-4. 
Park, I.K., Qian, D., Kiel, M., Becker, M.W., Pihalja, M., Weissman, I.L., Morrison, S.J., and 
Clarke, M.F. (2003). Bmi-1 is required for maintenance of adult self-renewing 
haematopoietic stem cells. Nature 423, 302-305. 
Pietersen, A.M., Evers, B., Prasad, A.A., Tanger, E., Cornelissen-Steijger, P., Jonkers, J., and 
van Lohuizen, M. (2008). Bmi1 regulates stem cells and proliferation and 
differentiation of committed cells in mammary epithelium. Curr Biol 18, 1094-1099. 
Ressler, S., Bartkova, J., Niederegger, H., Bartek, J., Scharffetter-Kochanek, K., Jansen-Durr, 
P., and Wlaschek, M. (2006). p16INK4A is a robust in vivo biomarker of cellular 
aging in human skin. Aging Cell 5, 379-389. 
Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001). Stem cells, cancer, and 
cancer stem cells. Nature 414, 105-111. 
Richie, E.R., Schumacher, A., Angel, J.M., Holloway, M., Rinchik, E.M., and Magnuson, T. 
(2002). The Polycomb-group gene eed regulates thymocyte differentiation and 
suppresses the development of carcinogen-induced T-cell lymphomas. Oncogene 
21, 299-306. 
Rodier, F., Campisi, J., and Bhaumik, D. (2007). Two faces of p53: aging and tumor 
suppression. Nucleic Acids Res 35, 7475-7484. 
www.intechopen.com
 Insights Into Stem Cell Aging 
 
259 
Ross, E.A., Anderson, N., and Micklem, H.S. (1982). Serial depletion and regeneration of the 
murine hematopoietic system. Implications for hematopoietic organization and the 
study of cellular aging. J Exp Med 155, 432-444. 
Saxena, V., Ondr, J.K., Magnusen, A.F., Munn, D.H., and Katz, J.D. (2007). The 
countervailing actions of myeloid and plasmacytoid dendritic cells control 
autoimmune diabetes in the nonobese diabetic mouse. J Immunol 179, 5041-5053. 
Schlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., Eden, E., 
Yakhini, Z., Ben-Shushan, E., Reubinoff, B.E., et al. (2007). Polycomb-mediated 
methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in 
cancer. Nat Genet 39, 232-236. 
Sharpless, N.E. (2005). INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 
576, 22-38. 
Siminovitch, L., Till, J.E., and McCulloch, E.A. (1964). Decline in Colony-Forming Ability of 
Marrow Cells Subjected to Serial Transplantation into Irradiated Mice. J Cell 
Physiol 64, 23-31. 
Toledo, F., and Wahl, G.M. (2006). Regulating the p53 pathway: in vitro hypotheses, in vivo 
veritas. Nat Rev Cancer 6, 909-923. 
Tyner, S.D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., 
Soron, G., Cooper, B., Brayton, C., et al. (2002). p53 mutant mice that display early 
ageing-associated phenotypes. Nature 415, 45-53. 
Valk-Lingbeek, M.E., Bruggeman, S.W., and van Lohuizen, M. (2004). Stem cells and cancer; 
the polycomb connection. Cell 118, 409-418. 
van der Lugt, N.M., Domen, J., Linders, K., van Roon, M., Robanus-Maandag, E., te Riele, 
H., van der Valk, M., Deschamps, J., Sofroniew, M., van Lohuizen, M., et al. (1994). 
Posterior transformation, neurological abnormalities, and severe hematopoietic 
defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev 8, 
757-769. 
van Lohuizen, M., Verbeek, S., Scheijen, B., Wientjens, E., van der Gulden, H., and Berns, A. 
(1991). Identification of cooperating oncogenes in E mu-myc transgenic mice by 
provirus tagging. Cell 65, 737-752. 
Voncken, J.W., Roelen, B.A., Roefs, M., de Vries, S., Verhoeven, E., Marino, S., Deschamps, J., 
and van Lohuizen, M. (2003). Rnf2 (Ring1b) deficiency causes gastrulation arrest 
and cell cycle inhibition. Proc Natl Acad Sci U S A 100, 2468-2473. 
Wang, L., Brown, J.L., Cao, R., Zhang, Y., Kassis, J.A., and Jones, R.S. (2004). Hierarchical 
recruitment of polycomb group silencing complexes. Mol Cell 14, 637-646. 
Wellner, U., Schubert, J., Burk, U.C., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., 
Vannier, C., Darling, D., zur Hausen, A., et al. (2009). The EMT-activator ZEB1 
promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell 
Biol 11, 1487-1495. 
Yang, M.H., Hsu, D.S., Wang, H.W., Wang, H.J., Lan, H.Y., Yang, W.H., Huang, C.H., Kao, 
S.Y., Tzeng, C.H., Tai, S.K., et al. (2010). Bmi1 is essential in Twist1-induced 
epithelial-mesenchymal transition. Nat Cell Biol 12, 982-992. 
www.intechopen.com
 Advances in Hematopoietic Stem Cell Research 
 
260 
Yilmaz, O.H., Kiel, M.J., and Morrison, S.J. (2006). SLAM family markers are conserved 
among hematopoietic stem cells from old and reconstituted mice and markedly 
increase their purity. Blood 107, 924-930. 
Zeggini, E., Scott, L.J., Saxena, R., Voight, B.F., Marchini, J.L., Hu, T., de Bakker, P.I., 
Abecasis, G.R., Almgren, P., Andersen, G., et al. (2008). Meta-analysis of genome-
wide association data and large-scale replication identifies additional susceptibility 
loci for type 2 diabetes. Nat Genet 40, 638-645. 
www.intechopen.com
Advances in Hematopoietic Stem Cell Research
Edited by Dr. Rosana Pelayo
ISBN 978-953-307-930-1
Hard cover, 464 pages
Publisher InTech
Published online 27, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book provides a comprehensive overview in our understanding of the biology and therapeutic potential of
hematopoietic stem cells, and is aimed at those engaged in stem cell research: undergraduate and
postgraduate science students, investigators and clinicians. Starting from fundamental principles in
hematopoiesis, Advances in Hematopoietic Stem Cell Research assemble a wealth of information relevant to
central mechanisms that may regulate differentiation, and expansion of hematopoietic stem cells in normal
conditions and during disease.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
A. Herrera-Merchan, I. Hidalgo, L. Arranz and S. Gonzalez (2012). Insights Into Stem Cell Aging, Advances in
Hematopoietic Stem Cell Research, Dr. Rosana Pelayo (Ed.), ISBN: 978-953-307-930-1, InTech, Available
from: http://www.intechopen.com/books/advances-in-hematopoietic-stem-cell-research/insights-into-stem-cell-
aging
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
